Ipamorelin is a synthetic growth hormone secretagogue and ghrelin receptor agonist. It is a short peptide that stimulates the body’s own release of growth hormone (GH) by activating the growth hormone secretagogue receptor type 1a (GHS-R1a), also known as the ghrelin receptor.
Ipamorelin is commonly discussed in the peptide and hormone-optimization space because it may increase endogenous GH release without directly administering growth hormone. However, unlike tesamorelin, ipamorelin is not FDA-approved for any medical indication. It is considered an investigational or unapproved peptide in the United States.
The FDA has also identified safety concerns regarding compounded ipamorelin products, including concerns related to peptide impurities, aggregation, and potential immunogenicity.
Ipamorelin acts primarily by binding to and activating the GHS-R1a receptor, the same receptor activated by ghrelin. This receptor is expressed in the pituitary gland and hypothalamus and plays a role in regulating growth hormone secretion.
Activation of GHS-R1a may result in:
Ipamorelin is described in the literature as a selective growth hormone secretagogue because early studies found that it stimulated GH release with less apparent stimulation of cortisol, prolactin, ACTH, LH, FSH, or TSH compared with some earlier growth hormone-releasing peptides.
The GH/IGF-1 axis governs two primary biological functions: Somatic Growth and Metabolism.
Growth (Somatic & Linear)
Metabolism
Research suggests ipamorelin may have several biologic effects related to growth hormone signaling. These potential benefits are based on limited human studies, animal studies, and mechanistic data.
Potential benefits may include:
It is important to note that ipamorelin has not been proven or FDA-approved for anti-aging, weight loss, bodybuilding, injury recovery, longevity, or hormone optimization.
Because ipamorelin is not FDA-approved, its full safety profile is not as well established as approved medications.
Potential risks may include:
In FDA review materials regarding compounding, the FDA noted that there are no FDA-approved drug products containing ipamorelin free base or ipamorelin acetate. The FDA also stated that compounded drugs containing ipamorelin acetate may pose safety concerns, including potential immunogenicity related to aggregation or peptide-related impurities.
Ipamorelin should generally be avoided or used only with extreme caution in individuals with:
Patients with diabetes, prediabetes, or metabolic syndrome may require careful monitoring because GH secretagogues can affect glucose metabolism.
Ipamorelin is not FDA-approved for any indication in the United States.
It is not FDA-approved for:
The FDA has reviewed ipamorelin-related bulk drug substances in the context of compounding and concluded that available information raised safety concerns and did not support inclusion on the 503A Bulks List.
Human Studies
Human research on ipamorelin is limited compared with FDA-approved peptide therapies.
A pharmacokinetic-pharmacodynamic study in healthy male volunteers evaluated intravenous ipamorelin and found that ipamorelin produced a dose-dependent increase in growth hormone release, with GH peaking shortly after administration and then declining.
A phase 2 randomized proof-of-concept study evaluated ipamorelin as a ghrelin-receptor agonist for postoperative ileus. This study explored safety and efficacy in a surgical setting, but ipamorelin did not become an FDA-approved therapy for this indication.
Animal & Preclinical Studies
Animal studies have evaluated ipamorelin as a selective growth hormone secretagogue and ghrelin mimetic.
Published animal and preclinical studies have shown that ipamorelin can:
These findings support biologic activity but do not prove safety or efficacy for common off-label uses in humans.
Human Studies
Animal & Preclinical Studies
Review Articles
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and reviewed for general accuracy; however, it may contain errors or omissions and should not replace professional medical judgment. Individuals should consult a qualified healthcare provider before beginning or changing any medical treatment.
Ipamorelin is not FDA-approved for any medical indication in the United States. Its use remains investigational, and any clinical use may be considered off-label or non-approved depending on context. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# Sermorelin